[en] Cytokines are small secreted proteins that among many functions also play key roles in the orchestration of inflammation in host defense and disease. Over the past years, a large number of biologics have been developed to target cytokines in disease, amongst which soluble receptor fusion proteins have shown some promise in pre-clinical studies. We have previously shown proof-of-concept for the therapeutic targeting of interleukin (IL)-33 in airway inflammation using a newly developed biologic, termed IL-33trap, comprising the ectodomains of the cognate receptor ST2 and the co-receptor IL-1RAcP fused into a single-chain recombinant fusion protein. Here we extend the biophysical and biological characterization of IL-33trap variants, and show that IL-33trap is a stable protein with a monomeric profile both at physiological temperatures and during liquid storage at 4°C. Reducing the N-glycan heterogeneity and complexity of IL-33trap via GlycoDelete engineering neither affects its stability nor its inhibitory activity against IL-33. We also report that IL-33trap specifically targets biologically active IL-33 splice variants. Finally, we document the generation and antagonistic activity of a single-chain IL-4/13trap, which inhibits both IL-4 and IL-13 signaling. Collectively, these results illustrate that single-chain soluble receptor fusion proteins against IL-4, IL-13, and IL-33 are novel biologics that might not only be of interest for research purposes and further interrogation of the role of their target cytokines in physiology and disease, but may also complement monoclonal antibodies for the treatment of allergic and other inflammatory diseases.
Holgado, Aurora; Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium ; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
Braun, Harald; Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium ; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
Verstraete, Kenneth; Center for Inflammation Research, Unit for Structural Biology, VIB, Ghent, Belgium ; Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
Vanneste, Domien ; Université de Liège - ULiège > GIGA > GIGA I3 - Immunophysiology ; Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium ; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
Callewaert, Nico; Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium ; Center for Medical Biotechnology, VIB, Ghent, Belgium
Savvides, Savvas N; Center for Inflammation Research, Unit for Structural Biology, VIB, Ghent, Belgium ; Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
Afonina, Inna S; Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium ; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
Beyaert, Rudi; Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium ; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
Language :
English
Title :
Single-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors.
Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, et al. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol. (2014) 27:33–48. 10.1177/03946320140270S103
Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R. VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand. Curr Med Res Opin. (2019) 35:1837–46. 10.1080/03007995.2019.1634952
Sastre J, Davila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. (2018) 28:139–50. 10.18176/jiaci.025429939132
Emma R, Morjaria JB, Fuochi V, Polosa R, Caruso M. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. (2018) 12:1753466618808490. 10.1177/175346661880849030354852
Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. (2014) 74:1379–410. 10.1007/s40265-014-0258-925034360
Church LD, McDermott MF. Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol. (2009) 5:14–5. 10.1038/ncprheum095919015646
Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes. (CAPS). J Inflamm Res. (2010) 3:1–8. 10.2147/JIR.S810922096352
Nishikawa K, Oishi A, Hata M, Miyake M, Ooto S, Yamashiro K, et al. Four-year outcome of aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Sci Rep. (2019) 9:3620. 10.1038/s41598-019-39995-530842468
Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. (2018) 9:1157. 10.3389/fphar.2018.0115730459597
Braun H Afonina IS Mueller C Beyaert R. Dichotomous function of IL-33 in health and disease: From biology to clinical implications. Biochem Pharmacol. (2018) 148:238–52. 10.1016/j.bcp.2018.01.01029309756
Chen WY, Tsai TH, Yang JL, Li LC. Therapeutic strategies for targeting IL-33/ST2 signalling for the treatment of inflammatory diseases. Cell Physiol Biochem. (2018) 49:349–58. 10.1159/00049288530138941
Chinthrajah S, Cao S, Liu C, Lyu S-C, Sindher SB, Long A, et al. Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy. JCI Insight. (2019) 4:e131347. 10.1172/jci.insight.13134731723064
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. (2005) 23:479–90. 10.1016/j.immuni.2005.09.015
Holgado A, Braun H, Van Nuffel E, Detry S, Schuijs MJ, Deswarte K, et al. IL-33trap is a novel IL-33-neutralizing biologic that inhibits allergic airway inflammation. J Allergy Clin Immunol. (2019) 144:204–15. 10.1016/j.jaci.2019.02.02830876911
Van der Jeught K, Sun Y, Fang Y, Zhou Z, Jiang H, Yu T, et al. ST2 as checkpoint target for colorectal cancer immunotherapy. JCI Insight. (2020) 5:136073. 10.1172/jci.insight.13607332376804
Ruegg TL, Pereira JH, Chen JC, DeGiovanni A, Novichkov P, Mutalik VK, et al. Jungle Express is a versatile repressor system for tight transcriptional control. Nat Commun. (2018) 9:3617. 10.1038/s41467-018-05857-3
Meuris L, Santens F, Elson G, Festjens N, Boone M, Dos Santos A, et al. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat Biotechnol. (2014) 32:485–9. 10.1038/nbt.288524752077
Ericsson UB, Hallberg BM, Detitta GT, Dekker N, Nordlund P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem. (2006) 357:289–98. 10.1016/j.ab.2006.07.02716962548
Menzen T, Friess W. High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants. J Pharm Sci. (2013) 102:415–28. 10.1002/jps.2340523212746
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. (2007) 7:715–25. 10.1038/nri215517703228
Huynh K, Partch CL. Analysis of protein stability and ligand interactions by thermal shift assay. Curr Protoc Protein Sci. (2015). 79:28.9.1–14. 10.1002/0471140864.ps2809s7925640896
Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. (2013) 32:1478–88. 10.1038/emboj.2013.7923584533
Tsuda H, Komine M, Karakawa M, Etoh T, Tominaga S, Ohtsuki M. Novel splice variants of IL-33: differential expression in normal and transformed cells. J Invest Dermatol. (2012) 132:2661–4. 10.1038/jid.2012.18022785132
Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, et al. Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc Natl Acad Sci USA. (2016) 113:8765–70. 10.1073/pnas.160191411327432971
Liu X, Hammel M, He Y, Tainer JA, Jeng US, Zhang L, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci USA. (2013) 110:14918–23. 10.1073/pnas.130865111023980170
Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun. (2017) 8:14937. 10.1038/ncomms1493728368013
Karo-Atar D, Bitton A, Benhar I, Munitz A. Therapeutic targeting of the interleukin-4/interleukin-13 signaling pathway: in allergy and beyond. BioDrugs. (2018) 32:201–20. 10.1007/s40259-018-0280-729736903
LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. (2008) 132:259–72. 10.1016/j.cell.2007.12.03018243101
Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. (2003) 9:47–52. 10.1038/nm81112483208
Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schoneich C, Winter G, et al. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci. (2012) 101:946–54. 10.1002/jps.2301822170395
Roberts CJ. Protein aggregation and its impact on product quality. Curr Opin Biotechnol. (2014) 30:211–7. 10.1016/j.copbio.2014.08.00125173826
Zhang L, Luo S, Zhang B. Glycan analysis of therapeutic glycoproteins. MAbs. (2016) 8:205–15. 10.1080/19420862.2015.1117719
Afonina IS Muller C Martin SJ Beyaert R. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity. (2015) 42:991–1004. 10.1016/j.immuni.2015.06.00326084020
Shakola F, Suri P, Ruggiu M. Splicing regulation of pro-inflammatory cytokines and chemokines: at the interface of the neuroendocrine and immune systems. Biomolecules. (2015) 5:2073–100. 10.3390/biom503207326371053
Vannella KM, Ramalingam TR, Borthwick LA, Barron L, Hart KM, Thompson RW, et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis. Sci Transl Med. (2016) 8:337ra365. 10.1126/scitranslmed.aaf193827147589
Kraft M, Worm M. Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol. (2017) 13:301–10. 10.1080/1744666X.2017.129213428165826
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. (2018) 378:2486–96. 10.1056/NEJMoa180409229782217
Godar M, Deswarte K, Vergote K, Saunders M, de Haard H, Hammad H, et al. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J Allergy Clin Immunol. (2018) 142:1185–93 e1184. 10.1016/j.jaci.2018.06.00229890236
Ramirez-Carrozzi V, Sambandam A, Zhou M, Yan D, Kang J, Wu X, et al. Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone. J Allergy Clin Immunol. (2017) 139:705–8.e706. 10.1016/j.jaci.2016.08.02627697499
Ito R, Maruoka S, Gon Y, Katano I, Takahashi T, et al. Recent advances in allergy research using humanized mice. Int J Mol Sci. (2019) 20:2740. 10.3390/ijms2011274031167385
